In a report released yesterday, Gianluca Tucci from Haywood reiterated a Buy rating on WELL Health Technologies Corp, with a price target of C$8.50.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Gianluca Tucci’s rating is based on WELL Health Technologies Corp’s strong performance and strategic initiatives. The company has demonstrated positive momentum through its majority-owned subsidiary, WELLSTAR, which is exceeding internal expectations due to robust organic growth and a promising acquisition pipeline. The adoption of the Nexus AI solution is accelerating, and recent acquisitions are expected to significantly boost annual recurring revenue, total revenue, and adjusted EBITDA, aligning with WELLSTAR’s long-term strategy.
Furthermore, WELL Health’s Canadian Clinics segment has updated its revenue guidance, projecting substantial growth for 2025. The acquisition of additional clinics is set to enhance revenue and EBITDA figures, with several targets under letters of intent. The extension and enhancement of WELL’s senior secured credit facility provide further financial flexibility. The company’s focus on digitizing and modernizing its clinics is expected to drive cost optimization and operational excellence, supporting the Buy rating.
According to TipRanks, Tucci is ranked #762 out of 9822 analysts.
In another report released on July 9, Stifel Nicolaus also maintained a Buy rating on the stock with a C$9.00 price target.